<p>Capital International Inc. CA 在第一季度減持強生（Johnson &amp; Johnson）股份，根據其最新向 SEC 提交的 13F 申報文件，持有公司股票 109,673 股，比期間減持 137,587 股，價值$17,349,000。</p>
<p>獲取 <strong>強生（Johnson &amp; Johnson）</strong> 警報：</p>
<ul>
<li>直覺外科股表現優於市場：高點在望</li>
</ul>
<p>其他一些機構投資者最近也調整了對 JNJ 的持倉。Etesian Wealth Advisors Inc.在第四季度增持了 0.7% 的強生股份。現在持有公司股票 11,093 股，價值$1,737,000，比期間增持 73 股。Jessup Wealth Management Inc.在第四季度增持了 4.8% 的強生股份。現在持有公司股票 10,776 股，價值$1,689,000，比期間增持 491 股。Eclectic Associates Inc. ADV 在第四季度增持了 2.9% 的強生股份。現在持有公司股票 9,432 股，價值$1,478,000，比上一季度增持 270 股。Strategic Wealth Investment Group LLC 在第四季度增持了 18.0% 的強生股份。現在持有公司股票 34,989 股，價值$5,484,000，比期間增持 5,335 股。最後，Carlson Capital Management 在第四季度增持了 13.1% 的強生股份。現在持有公司股票 15,734 股，價值$2,466,000，比上一季度增持 1,822 股。對沖基金和其他機構投資者持有公司股份的比例為 69.55%。</p>
<h2>強生（Johnson &amp; Johnson）股價上漲 0.7%</h2>
<p>JNJ 股票週五在午盤交易中上漲$1.04，報價$160.68。公司股票交易量為 8,356,432 股，相比平均交易量 7,349,373 股有所增加。強生股票一年內最低價為$143.13，最高價為$175.97。公司的 50 天移動平均價格為$148.74，200 天移動平均價格為$153.24。公司的流動比率為 1.17，速動比率為 0.94，負債權益比為 0.36。股票市值為$386.71 十億美元，市盈率為 10.02，市盈增長比為 2.56，貝塔係數為 0.52。</p>
<ul>
<li>MarketBeat 周評 - 7/15 - 7/19</li>
</ul>
<p>強生（Johnson &amp; Johnson）（NYSE:JNJ - 獲取免費報告）上次公佈季度財報是在 7 月 17 日星期三。公司報告該季度每股收益為$2.82，超過分析師預期的$2.71，超出$0.11。強生公司的淨資產收益率為 36.79%，淨利潤率為 46.34%。該季度公司營收為 224.5 億美元，超過分析師預期的 223.3 億美元。去年同期，該公司每股收益為$2.80。公司營收同比增長 4.3%。賣方分析師預計，強生公司今年將實現每股盈利 10.07 美元。</p>
<h2>強生（Johnson &amp; Johnson）宣佈股息</h2>
<p>公司最近宣佈每季度支付股息，將於 9 月 10 日週二支付。股東記錄日為 8 月 27 日週二，將支付每股$1.24 的股息。該股息的除息日為 8 月 27 日週二。這代表年化基礎上的$4.96 股息和 3.09% 的收益率。強生公司的派息比率為 30.92%。</p>
<h2>分析師設定新的股價目標</h2>
<ul>
<li>這家醫療巨頭股價反彈：最低漲幅 15%</li>
</ul>
<p>JNJ 最近受到多家分析師報告的關注。滙豐銀行將強生股票評級從 “持有” 調高至 “買入”，並將目標股價從 169.00 美元提高至 170.00 美元。戴娃美國將強生股票評級從 “強買” 下調至 “持有”。卡恩特菲茨傑拉德重申對強生股票的 “超配” 評級，並設定了 215.00 美元的目標股價。加拿大皇家銀行重申對強生股票的 “表現優異” 評級，並在 7 月 18 日星期四的研究報告中設定了 175.00 美元的目標股價。最後，摩根士丹利將強生股票的目標股價從 167.00 美元上調至 169.00 美元，並給予公司 “等權重” 評級。八家分析師對該股票給予持有評級，六家給予買入評級，一家給予強烈買入評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “中等買入”，平均目標股價為 173.00 美元。</p>
<p>閲讀我們關於 JNJ 的最新研究報告</p>
<h2>強生（Johnson &amp; Johnson）公司簡介（免費報告）</h2>
<p>強生及其子公司在全球範圍內從事醫療保健領域的各種產品的研究、開發、製造和銷售。該公司的創新藥物部門提供各種治療領域的產品，包括免疫學，如類風濕性關節炎、銀屑病性關節炎、炎症性腸病和牛皮癬；傳染病，包括艾滋病；神經科學，包括情緒障礙、神經退行性疾病和精神分裂症；腫瘤學，如前列腺癌、血液惡性腫瘤、肺癌和膀胱癌；心血管和代謝，包括血栓形成、糖尿病和黃斑變性；以及肺動脈高壓，通過零售商、批發商、分銷商、醫院和醫療專業人士供處方使用。</p>
<h2>閲讀更多</h2>
<ul>
<li>五隻我們喜歡的股票，勝過強生</li>
<li>消費者價格指數衡量什麼？</li>
<li>3M 驚喜和反彈加速：現在入場不算晚</li>
<li>複利利息如何計算？</li>
<li>斯凱奇股票在消費者自由選擇行業表現強勁</li>
<li>什麼是盈利驚喜？</li>
<li>科技股下跌，這些股票提供購買機會</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>這則即時新聞警報是由敍事科技和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關本故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
<p>→ 下一個加密百萬機會（來自 Crypto 101 Media）(廣告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04Nzk0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04Nzk0"/></p>
<h2>現在是否值得投資$1,000 美元購買強生股票？</h2>
<p>在考慮購買強生股票之前，您需要聽到這個消息。</p>
<p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已確定了五隻頂級分析師悄悄告訴客户現在購買的股票，而強生股票不在名單上。</p>
<p>儘管強生目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

強生

<p>根據其最近向美國證券交易委員會提交的文件，Capital International Inc. CA 在第一季度期間將其持有的強生股份減少了 55.6%。該基金在此期間賣出了 137,587 股，持有公司股票的數量為 109,673 股</p>

<p>Capital International Inc. CA reduced its stake in Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 55.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 109,673 shares of the company's stock after selling 137,587 shares during the period. Capital International Inc. CA's holdings in Johnson &amp; Johnson were worth $17,349,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Capital International Inc. CA 在第一季度減持強生（Johnson &amp; Johnson）股份，根據其最新向 SEC 提交的 13F 申報文件，持有公司股票 109,673 股，比期間減持 137,587 股，價值$17,349,000。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<ul>
<li>Intuitive Surgical Stock Outperforms Market: Highs on the Horizon</li>
</ul>
<div class="lb-trans"><p>獲取 <strong>強生（Johnson &amp; Johnson）</strong> 警報：</p>
<ul>
<li>直覺外科股表現優於市場：高點在望</li>
</ul>
</div><p>A number of other institutional investors have also recently made changes to their positions in JNJ. Etesian Wealth Advisors Inc. raised its holdings in Johnson &amp; Johnson by 0.7% during the 4th quarter. Etesian Wealth Advisors Inc. now owns 11,093 shares of the company's stock valued at $1,737,000 after buying an additional 73 shares during the period. Jessup Wealth Management Inc boosted its stake in shares of Johnson &amp; Johnson by 4.8% during the 4th quarter. Jessup Wealth Management Inc now owns 10,776 shares of the company's stock worth $1,689,000 after purchasing an additional 491 shares during the period. Eclectic Associates Inc. ADV grew its stake in shares of Johnson &amp; Johnson by 2.9% during the fourth quarter. Eclectic Associates Inc. ADV now owns 9,432 shares of the company's stock valued at $1,478,000 after buying an additional 270 shares during the last quarter. Strategic Wealth Investment Group LLC raised its holdings in shares of Johnson &amp; Johnson by 18.0% in the fourth quarter. Strategic Wealth Investment Group LLC now owns 34,989 shares of the company's stock worth $5,484,000 after buying an additional 5,335 shares during the period. Finally, Carlson Capital Management lifted its stake in shares of Johnson &amp; Johnson by 13.1% during the 4th quarter. Carlson Capital Management now owns 15,734 shares of the company's stock worth $2,466,000 after acquiring an additional 1,822 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.</p>
<div class="lb-trans"><p>其他一些機構投資者最近也調整了對 JNJ 的持倉。Etesian Wealth Advisors Inc.在第四季度增持了 0.7% 的強生股份。現在持有公司股票 11,093 股，價值$1,737,000，比期間增持 73 股。Jessup Wealth Management Inc.在第四季度增持了 4.8% 的強生股份。現在持有公司股票 10,776 股，價值$1,689,000，比期間增持 491 股。Eclectic Associates Inc. ADV 在第四季度增持了 2.9% 的強生股份。現在持有公司股票 9,432 股，價值$1,478,000，比上一季度增持 270 股。Strategic Wealth Investment Group LLC 在第四季度增持了 18.0% 的強生股份。現在持有公司股票 34,989 股，價值$5,484,000，比期間增持 5,335 股。最後，Carlson Capital Management 在第四季度增持了 13.1% 的強生股份。現在持有公司股票 15,734 股，價值$2,466,000，比上一季度增持 1,822 股。對沖基金和其他機構投資者持有公司股份的比例為 69.55%。</p>
</div><h2>Johnson &amp; Johnson Stock Up 0.7 %</h2>
<div class="lb-trans"><h2>強生（Johnson &amp; Johnson）股價上漲 0.7%</h2>
</div><p>Shares of JNJ traded up $1.04 during midday trading on Friday, hitting $160.68. 8,356,432 shares of the company's stock traded hands, compared to its average volume of 7,349,373. Johnson &amp; Johnson has a 1 year low of $143.13 and a 1 year high of $175.97. The firm's fifty day moving average is $148.74 and its 200-day moving average is $153.24. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $386.71 billion, a price-to-earnings ratio of 10.02, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52.</p>
<ul>
<li>MarketBeat Week in Review – 7/15 - 7/19</li>
</ul>
<div class="lb-trans"><p>JNJ 股票週五在午盤交易中上漲$1.04，報價$160.68。公司股票交易量為 8,356,432 股，相比平均交易量 7,349,373 股有所增加。強生股票一年內最低價為$143.13，最高價為$175.97。公司的 50 天移動平均價格為$148.74，200 天移動平均價格為$153.24。公司的流動比率為 1.17，速動比率為 0.94，負債權益比為 0.36。股票市值為$386.71 十億美元，市盈率為 10.02，市盈增長比為 2.56，貝塔係數為 0.52。</p>
<ul>
<li>MarketBeat 周評 - 7/15 - 7/19</li>
</ul>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating analysts' consensus estimates of $2.71 by $0.11. Johnson &amp; Johnson had a return on equity of 36.79% and a net margin of 46.34%. The company had revenue of $22.45 billion during the quarter, compared to analysts' expectations of $22.33 billion. During the same period last year, the business posted $2.80 earnings per share. The firm's revenue was up 4.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Johnson &amp; Johnson will post 10.07 earnings per share for the current year.</p>
<div class="lb-trans"><p>強生（Johnson &amp; Johnson）（NYSE:JNJ - 獲取免費報告）上次公佈季度財報是在 7 月 17 日星期三。公司報告該季度每股收益為$2.82，超過分析師預期的$2.71，超出$0.11。強生公司的淨資產收益率為 36.79%，淨利潤率為 46.34%。該季度公司營收為 224.5 億美元，超過分析師預期的 223.3 億美元。去年同期，該公司每股收益為$2.80。公司營收同比增長 4.3%。賣方分析師預計，強生公司今年將實現每股盈利 10.07 美元。</p>
</div><h2>Johnson &amp; Johnson Announces Dividend</h2>
<div class="lb-trans"><h2>強生（Johnson &amp; Johnson）宣佈股息</h2>
</div><p>The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a yield of 3.09%. Johnson &amp; Johnson's payout ratio is 30.92%.</p>
<div class="lb-trans"><p>公司最近宣佈每季度支付股息，將於 9 月 10 日週二支付。股東記錄日為 8 月 27 日週二，將支付每股$1.24 的股息。該股息的除息日為 8 月 27 日週二。這代表年化基礎上的$4.96 股息和 3.09% 的收益率。強生公司的派息比率為 30.92%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<ul>
<li>This Medical Giant's Stock Rebounds: A 15% Upside Is the Minimum</li>
</ul>
<div class="lb-trans"><h2>分析師設定新的股價目標</h2>
<ul>
<li>這家醫療巨頭股價反彈：最低漲幅 15%</li>
</ul>
</div><p>JNJ has been the subject of a number of recent analyst reports. HSBC raised shares of Johnson &amp; Johnson from a &#34;hold&#34; rating to a &#34;buy&#34; rating and boosted their target price for the company from $169.00 to $170.00 in a research note on Thursday, April 18th. Daiwa America downgraded Johnson &amp; Johnson from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday. Cantor Fitzgerald restated an &#34;overweight&#34; rating and set a $215.00 price target on shares of Johnson &amp; Johnson in a research note on Monday, July 1st. Royal Bank of Canada reaffirmed an &#34;outperform&#34; rating and issued a $175.00 price objective on shares of Johnson &amp; Johnson in a research note on Thursday, July 18th. Finally, Morgan Stanley raised their target price on shares of Johnson &amp; Johnson from $167.00 to $169.00 and gave the company an &#34;equal weight&#34; rating in a research report on Thursday, July 18th. Eight analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $173.00.</p>
<div class="lb-trans"><p>JNJ 最近受到多家分析師報告的關注。滙豐銀行將強生股票評級從 “持有” 調高至 “買入”，並將目標股價從 169.00 美元提高至 170.00 美元。戴娃美國將強生股票評級從 “強買” 下調至 “持有”。卡恩特菲茨傑拉德重申對強生股票的 “超配” 評級，並設定了 215.00 美元的目標股價。加拿大皇家銀行重申對強生股票的 “表現優異” 評級，並在 7 月 18 日星期四的研究報告中設定了 175.00 美元的目標股價。最後，摩根士丹利將強生股票的目標股價從 167.00 美元上調至 169.00 美元，並給予公司 “等權重” 評級。八家分析師對該股票給予持有評級，六家給予買入評級，一家給予強烈買入評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “中等買入”，平均目標股價為 173.00 美元。</p>
</div><p><strong>Read Our Latest Research Report on JNJ</strong></p>
<div class="lb-trans"><p>閲讀我們關於 JNJ 的最新研究報告</p>
</div><h2>Johnson &amp; Johnson Company Profile (Free Report)</h2>
<div class="lb-trans"><h2>強生（Johnson &amp; Johnson）公司簡介（免費報告）</h2>
</div><p>Johnson &amp; Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.</p>
<div class="lb-trans"><p>強生及其子公司在全球範圍內從事醫療保健領域的各種產品的研究、開發、製造和銷售。該公司的創新藥物部門提供各種治療領域的產品，包括免疫學，如類風濕性關節炎、銀屑病性關節炎、炎症性腸病和牛皮癬；傳染病，包括艾滋病；神經科學，包括情緒障礙、神經退行性疾病和精神分裂症；腫瘤學，如前列腺癌、血液惡性腫瘤、肺癌和膀胱癌；心血管和代謝，包括血栓形成、糖尿病和黃斑變性；以及肺動脈高壓，通過零售商、批發商、分銷商、醫院和醫療專業人士供處方使用。</p>
</div><h2>Read More</h2>
<ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>What does consumer price index measure?</li>
<li>3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In</li>
<li>How is Compound Interest Calculated?</li>
<li>Skechers Stock Shows Strength Among Consumer Discretionary Sector</li>
<li>What is an Earnings Surprise?</li>
<li>Tech Stocks Tumble, These Stocks Present Buying Opportunity</li>
</ul>
<div class="lb-trans"><h2>閲讀更多</h2>
<ul>
<li>五隻我們喜歡的股票，勝過強生</li>
<li>消費者價格指數衡量什麼？</li>
<li>3M 驚喜和反彈加速：現在入場不算晚</li>
<li>複利利息如何計算？</li>
<li>斯凱奇股票在消費者自由選擇行業表現強勁</li>
<li>什麼是盈利驚喜？</li>
<li>科技股下跌，這些股票提供購買機會</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由敍事科技和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關本故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><p>→ Next opportunity for crypto millions (From Crypto 101 Media)(Ad)</p>
<div class="lb-trans"><p>→ 下一個加密百萬機會（來自 Crypto 101 Media）(廣告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04Nzk0" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8794&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Johnson &amp; Johnson right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資$1,000 美元購買強生股票？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮購買強生股票之前，您需要聽到這個消息。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已確定了五隻頂級分析師悄悄告訴客户現在購買的股票，而強生股票不在名單上。</p>
</div><p>While Johnson &amp; Johnson currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管強生目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Capital International Inc. CA 出售了 137,587 股強生公司（NYSE:JNJ）的股票